Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.5552W HIGH $15.74
Volume
85.75 K
Value Traded
9.23 M
Short % Float
2.75%
+42.18%Week
+8.13%1 Month
+229.36%3 Month
-41.72%6 Month
-92.15%5 Year
-95.8%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
32.87 M
EPS (TTM)
-9.34
P/E Ratio
-
Ent. Value
12.78 M
Total Shares
4.58 M
Float Shares
3.83 M
Insiders
16.30%
Institutions
47.86%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
NXTC Catalyst Timeline
Dated clinical, regulatory and corporate events for NextCure, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for NextCure, Inc.
310Total events
14Upcoming
60Tier-1 (high impact)
2019 to 2029Coverage
Upcoming catalysts 2
Event history 50
◆AcquisitionCorporate
Xcellon Biologics signs definitive agreement to acquire NextCure's GMP manufacturing facility
▲Partnership / LicenseLNCB74Corporate
Entered into Transition and Continuation Agreement with LigaChem for LNCB74
▼Restructuring LayoffsCorporate
Advanced restructuring initiatives to reduce operating expenses
▲Partnership / LicenseAVR-001Corporate
Avere completes ex-Greater China exclusive licensing agreement with Hansoh for AVR-001
IL-23-driven inflammatory diseasessource ↗
▲Full ResultsAVR-001Clinical Data
Phase 1b psoriasis data from Hansoh trial reported
psoriasissource ↗
▼Program DiscontinuationSIM0505DiscontinuedCorporate
Stopped screening, consenting, and enrolling new patients in SIM0505 studies
◆Enrollment UpdateSIM0505DiscontinuedTrial
Increase in U.S. trial sites and expansion into Canada and Europe
gynecologic cancerssource ↗
◆Enrollment UpdateLNCB74Trial
Trial progress update planned for LNCB74 Phase 1 dose escalation
breast and gynecological cancers, adenoid cystic carcinoma type 1source ↗
▼Equity OfferingCorporate
Avere Therapeutics private financing expected to generate ~$320M gross proceeds
◆Oral PresentationSIM0505DiscontinuedPresentation
Virtual KOL Event to discuss ASCO 2026 data
gynecologic cancerssource ↗
◆Poster PresentationSIM0505DiscontinuedPresentation
Poster presentation of Phase 1 data for SIM0505 at ASCO 2026
advanced solid tumorssource ↗
◆Oral PresentationSIM0505DiscontinuedPresentation
Phase 1 dose escalation data to be presented at ASCO 2026
advanced solid tumors, gynecological cancers, PROCsource ↗
◆Oral PresentationSIM0505DiscontinuedPresentation
Presentation at ASCO 2026
advanced solid tumors, ovarian cancer, platinum resistant ovarian cancersource ↗
▲Fast Track DesignationSIM0505DiscontinuedDesignation
FDA granted Fast Track designation for SIM0505 in PROC
platinum-resistant ovarian cancersource ↗
▲First Patient DosedSIM0505DiscontinuedTrial
Initiation of dose optimization portion of Phase 1 study for SIM0505 in PROC
platinum-resistant ovarian cancersource ↗
▲Trial InitiationSIM0505DiscontinuedTrial
Initiated Phase 1 dose optimization segment in gynecologic cancers
gynecologic cancers (PROC focus)source ↗
▲Fast Track DesignationSIM0505DiscontinuedDesignation
FDA granted Fast Track designation for SIM0505 in platinum-resistant ovarian cancer
platinum-resistant ovarian cancersource ↗
●Enrollment UpdateSIM0505DiscontinuedTrial
59 patients enrolled in Phase 1 dose escalation as of April 7, 2026 data cutoff
advanced solid tumorssource ↗
◆Topline ReadoutSIM0505DiscontinuedClinical Data
Phase 1 dose escalation data update anticipated in Q2 2026
advanced solid tumorssource ↗
▲Trial InitiationSIM0505DiscontinuedTrial
Dose optimization in ovarian cancer expected to begin in Q2 2026
platinum-resistant ovarian cancersource ↗
◆AbstractSIM0505DiscontinuedPresentation
Abstract accepted for ASCO 2026
advanced solid tumors, ovarian cancer, platinum resistant ovarian cancersource ↗
▲Enrollment UpdateLNCB74Trial
Phase 1 dose escalation expanded into higher dose cohorts
advanced solid tumorssource ↗
◆Timing GuidanceSIM0505DiscontinuedPresentation
Proof of concept data readout for SIM0505 (CDH6 ADC)
cancersource ↗
◆Timing GuidanceLNCB74Presentation
Proof of concept data readout for LNCB74 (B7-H4 ADC)
cancersource ↗
▲Runway Guidance UpdateCorporate
Cash runway guidance: funds operations into second half of 2026
◆Oral PresentationPresentation
NextCure to present at Piper Sandler 37th Annual Healthcare Conference
▲First Patient DosedSIM0505DiscontinuedTrial
First US patient dosed in Phase 1 trial for SIM0505
cancersource ↗
▲IND ClearanceLNCB74IND
FDA clearance for LNCB74 protocol amendment to add higher dose escalation cohorts
cancersource ↗
▲First Patient DosedSIM0505DiscontinuedTrial
First patient dosed in U.S. in Phase 1 trial of SIM0505
advanced solid tumorssource ↗
◆Timing GuidanceSIM0505DiscontinuedPresentation
Program update on SIM0505 expected by Q4 2025
cancersource ↗
◆Oral PresentationPresentation
Fireside chat at H.C. Wainwright 27th Annual Global Investment Conference
▲Partnership / LicenseSIM0505DiscontinuedCorporate
Strategic partnership with Simcere Zaiming for SIM0505 (CDH6 ADC)
cancersource ↗
▲Oral PresentationNC605Presentation
Preclinical data presented at Brittle Bone Society Meeting
osteogenesis imperfectasource ↗
◆First Patient DosedSIM0505DiscontinuedTrial
Expected to begin clinical testing in the U.S. in Q3 2025
solid tumorssource ↗
◆Enrollment UpdateLNCB74Trial
Plan to initiate backfill cohorts in second half of 2025
multiple cancerssource ↗
Past FDA Catalysts and PDUFA Decisions
How NXTC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | SIM0505 (novel antibody-drug conjugate targeting CDH6) | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D32 / 100
Pipeline Score
$16M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.5x
rNPV / MCap
Top 63%
Micro Cap(rank 414 of 657)
Percentile Rank
NextCure, Inc. faces pipeline headwinds (32/100), with $1.2B risk-adjusted pipeline value, led by NC318 in Advanced Non-small Cell Lung Cancer (Phase 2), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NC318 Small moleculeNCT04699123 | Advanced Non-small Cell Lung Cancer | Phase 2 | ACTIVE NOT_RECRUITING | 159 | Dec 30, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every NXTC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SIM0505 Fast Track | gynecologic cancers | Phase 1 | 2026-06-01 | In a Phase 1 trial of SIM0505 for gynecologic cancers, the drug demonstrated a 55% overall response rate (ORR) at 12 weeks, with 52.9% in ovarian cancer and 66.7% in uterine serous carcinoma, within a therapeutic dose range of 4.8 · 8.0 mg/kg.Read More | NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Simcere Zaiming, Inc.Former 10% Owner | Sell | -30,000 308,636 held | $6.16 | 08/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NXTC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | 0 % (-100 %) | 356.00 K | 222.65 K |
NXTC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NXTC ranks across every disease it competes in
Competitive Position is a premium feature
See how NXTC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNXTC News
NXTC▲ +17.1%on this news· ran to +42% by day 3
Xcellon Biologics Acquires GMP Manufacturing Facility from NextCure, Becoming an End-to-End CRDMO for Next-Generation Bioconjugates and Complex Biologics
Xcellon Biologics has acquired a GMP manufacturing facility from NextCure, enhancing its capabilities as a comprehensive CRDMO for bioconjugates and complex biologics. The facility will support the development of antibody-based therapeutics from discovery to clinical supply. CEO Abhishake Chhibber emphasizes the importance of this acquisition in strengthening the U.S. biotechnology ecosystem.
Read more →NXTC▲ +17.1%on this news· ran to +42% by day 3shared move
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001
Avere Therapeutics has announced a $500 million private placement aimed at supporting the development of its once-weekly oral IL-23 therapy, AVR-001. This financing, backed by a prominent investor syndicate, is expected to fully fund Avere's operational plans through 2029. The funding is seen as a significant boost to the company's balance sheet.
Read more →NXTCNextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
NextCure, Inc. announced a proposed merger with Avere Therapeutics, aiming to close in the second half of 2026. The merger is expected to generate approximately $320 million in gross proceeds. Despite a net loss of $14.9 million for Q2 2026, the company is focused on preserving capital and supporting ongoing clinical programs. Restructuring initiatives have been implemented to reduce operating expenses.
Read more →NXTC▲ +201.8%on this news
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
NextCure and Avere Therapeutics have announced a merger to enhance the development of AVR-001, an oral IL-23 therapy for inflammatory diseases. The merger is supported by a $320 million private investment, ensuring sufficient funding for upcoming clinical trials. The combined entity will operate under the name Avere Therapeutics, Inc. and is expected to trade on Nasdaq as AVRX.
Read more →NXTCNXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
NextCure, Inc. announced the replay of its virtual KOL event discussing the promising Phase 1 dose escalation data for SIM0505, an investigational ADC targeting gynecologic cancers. The event featured expert insights on the efficacy of SIM0505 in treating ovarian cancer and uterine serous carcinoma. This follows the ASCO 2026 presentation, where the company shared its first clinical efficacy results.
Read more →NXTC▼ -45.5%on this news
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
NextCure presented promising Phase 1 data for SIM0505 at ASCO 2026, showing a 55% objective response rate in gynecologic cancers, including 52.9% in ovarian cancer and 66.7% in uterine serous carcinoma. The therapy demonstrated a favorable safety profile in heavily pretreated patients. NextCure plans to continue dose optimization and will host a virtual KOL event to discuss these results.
Read more →NXTC▼ -5%on this news
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
NextCure, Inc. reported a business update and financial results for Q1 2026, highlighting the Fast Track designation for SIM0505 in treating platinum-resistant ovarian cancer. The company plans to present Phase 1 data at ASCO 2026 and has initiated a dose optimization study. Despite a net loss of $9.8 million, NextCure aims to expand its trial sites into Canada and Europe.
Read more →NXTCNextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
NextCure and Simcere Zaiming have initiated the dose optimization phase of their Phase 1 study for SIM0505, targeting platinum-resistant ovarian cancer. The investigational ADC aims to finalize dose selection and expand its clinical footprint. Phase 1 data is expected to be presented at ASCO 2026, highlighting the development progress.
Read more →NXTC▼ -6.2%on this news
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
NextCure has announced that Phase 1 data for SIM0505, an investigational antibody drug conjugate targeting CDH6, will be presented at ASCO 2026. This presentation signifies an important milestone in NextCure's collaborative clinical approach and commitment to developing innovative cancer therapies. SIM0505 is currently being evaluated for its effectiveness in treating advanced solid tumors, including platinum-resistant ovarian cancer. The presentation is scheduled for June 1, 2026, in Chicago, Illinois.
Read more →NXTCNextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
NextCure, Inc. has received Fast Track designation from the FDA for SIM0505, an investigational antibody drug conjugate aimed at treating platinum-resistant ovarian cancer. This designation will facilitate closer collaboration with the FDA, expediting the development process. The company plans to initiate dose optimization in Q2 2026 and present Phase 1 data at the ASCO conference in 2026.
Read more →NXTCNextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
NextCure, Inc. and Simcere Zaiming Pharmaceutical Co., Ltd. have announced that an abstract for their investigational antibody drug conjugate, SIM0505, has been accepted for presentation at the ASCO 2026 meeting. The ongoing Phase 1 study is focused on advanced solid tumors, particularly platinum-resistant ovarian cancer. This development highlights the potential of SIM0505 in cancer treatment.
Read more →NXTCNextCure Provides Business Update and Reports Full Year 2025 Financial Results
NextCure, Inc. has announced its business update and 2025 financial results, highlighting its expectations for a transformative 2026 driven by advancements in its SIM0505 program. The company aims to present dose escalation data from a Phase 1 trial and is set to enroll patients for a new study focusing on platinum-resistant ovarian cancer. Despite positive advancements, NextCure faces financial challenges, including a reported net loss and dependency on funding. The development of its antibody-drug conjugates demonstrates potential for impactful cancer therapies amid a backdrop of financial stringency.
Read more →NXTCNextCure Provides Business Update
NextCure, Inc. has provided a business update on its two antibody drug conjugate (ADC) programs, SIM0505 and LNCB74. SIM0505 is expected to have Phase 1 dose escalation data available in Q2 2026, while LNCB74 is currently undergoing Phase 1 trials. The company also reported its preliminary cash position for year-end 2025.
Read more →NXTCNextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
NextCure, Inc. will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3rd. The event will be held in New York City and will include a live audio webcast available on their website. NextCure focuses on developing innovative cancer therapies, particularly for patients who do not respond to existing treatments.
Read more →NXTCNextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
NextCure, Inc. has successfully closed a $21.5 million private placement in public equity (PIPE), primarily led by several healthcare-focused funds. This financing is intended to bolster NextCure's working capital and ensures that the company's cash runway extends into the first half of 2027, beyond the expected data readouts from their antibody drug conjugate programs in the first half of 2026. The PIPE offering included the issuance of common stock and pre-funded warrants, with H.C. Wainwright & Co. serving as the exclusive placement agent.
Read more →NXTC▲ +9%on this news· ran to +19% by day 3shared move
NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules
NextCure, Inc. has announced a private placement of common stock, raising approximately $21.5 million. The offering, priced at $8.52 per share, involves institutional investors and is expected to close on November 13, 2025. The funds will be used for general working capital and to support ongoing clinical programs, extending the company's cash runway into the first half of 2027.
Read more →NXTCNextCure Provides Business Update and Reports Third Quarter 2025 Financial Results
NextCure, Inc. has provided a business update and reported its financial results for Q3 2025. The company is advancing its antibody-drug conjugate (ADC) programs, including the initiation of a Phase 1 trial for SIM0505 in the U.S. and receiving FDA clearance for LNCB74's protocol amendment. NextCure expects to share proof of concept data for both therapies in the first half of 2026.
Read more →NXTC▲ +27.8%on this news· ran to +75% by day 1
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
NextCure, Inc. and Simcere Zaiming have announced the dosing of the first patient in the U.S. as part of the ongoing Phase 1 trial of SIM0505, an antibody drug conjugate targeting advanced solid tumors. The trial, initially launched in China, is now expanding to include U.S. patients, with promising safety and efficacy data reported. The companies aim to present proof-of-concept data in the first half of 2026.
Read more →About NextCure, Inc.
Headquarters9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD, 20705
BIOPHARMAWATCH ELITE PLUS
Trade the next NXTC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime